Is Compounded Semaglutide Legal in 2026?

Broad "essentially a copy" compounding of semaglutide is no longer permitted. The FDA declared the semaglutide shortage resolved in February 2025, ending the exemption that allowed pharmacies to compound at scale. Only patient-specific, clinically-justified compounding from licensed 503A pharmacies remains permitted — and the FDA has proposed further restrictions on 503B compounders as well.

What happened: the shortage exemption and its end

During 2022–2024, Ozempic and Wegovy were on the FDA's drug shortage list due to high demand and manufacturing constraints. Under the Federal Food, Drug, and Cosmetic Act, this shortage status created a specific exemption: licensed compounding pharmacies could prepare essentially a copy of a shortage drug without it being considered an illegal copy of an approved product.

This is what allowed a large number of telehealth companies to offer compounded semaglutide at lower prices during that window — it was a lawful path under the shortage exemption. That exemption ended when the FDA removed semaglutide from the shortage list in February 2025.

What changed after February 2025

Once semaglutide was removed from the shortage list:

• The shortage-compounding exemption for 503A and 503B pharmacies no longer applied to semaglutide.
• Producing semaglutide essentially as a copy of an approved drug (Wegovy / Ozempic) became impermissible under the rules applicable to those pharmacy categories.
• The FDA issued warning letters to compounding facilities that continued offering semaglutide outside the permitted conditions.
• The FDA also proposed removing semaglutide from the 503B bulks list, which would further restrict large-scale compounding operations that had relied on that category.

What is still permitted: patient-specific 503A compounding

Not all compounding became impermissible. 503A pharmacies — state-licensed traditional compounders — can still prepare patient-specific formulations when:

• There is a valid prescription from a licensed prescriber
• There is a documented, clinically-specific reason the commercially available product doesn't meet the patient's individual needs (for example, an allergy to an excipient in the brand product, or a need for a dose or form not commercially available)
• The compounding is not from a bulk drug substance on a list that limits 503A activity

This is a narrow window — it is not a path for telehealth platforms to offer broadly available compounded semaglutide to large populations. The language "patient-specific" is meaningful: it requires a clinical rationale for this patient, not just a preference for a lower price.

What this means for you

If you're currently on compounded semaglutide obtained before the shortage ended, your prescribing clinician is the right person to talk to about what happens next. If you're weighing options for how to access a GLP-1 affordably, the affordability article covers the legitimate routes — manufacturer savings programs, cash-pay telehealth with brand products, and direct-pay clinics. Grey-market or unregulated sources carry risks — purity, dosing accuracy and sterility are not guaranteed — and are worth avoiding regardless of cost.

Frequently asked